Survodutide is a dual agonist of the GLP-1 and glucagon receptors, originally developed as a treatment for Type-2 Diabetes and obesity. Like other GLP-1 drugs, it suppresses appetite, increases fat oxidation, and supports metabolic activity. Survodutide has also shown promise as a treatment for non-cirrhotic metabolic-dysfunction-associated steatohepatitis (MASH) and moderate liver fibrosis (F2–F3 stage).
For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, and must not be misused in any way that contravenes MHRA regulations or applicable laws.
Survodutide is a dual agonist of the GLP-1 and glucagon receptors, originally developed as a treatment for Type-2 Diabetes and obesity. Like other GLP-1 drugs, it suppresses appetite, increases fat oxidation, and supports metabolic activity. Survodutide has also shown promise as a treatment for non-cirrhotic metabolic-dysfunction-associated steatohepatitis (MASH) and moderate liver fibrosis (F2–F3 stage).
Benefits
At 46 weeks, participants lost an average of 6 inches from waist circumference
19% total body weight loss at 4.8mg weekly
Significant reduction in blood pressure at 2.4mg or higher
Potentially beneficial for cardiovascular health
Ongoing weight loss past 46 weeks suggests longer-term use may yield greater fat reduction
Possible Side Effects
Survodutide shows milder side effects than other GLP-1 drugs in clinical trials. Reported side effects include:
Injection site irritation (redness, swelling, itching)
Nausea
Vomiting
Diarrhea
Contraindications
Monitor patients on antihypertensive medications — Survodutide may interact with blood pressure meds
Do not take if pregnant or breastfeeding
Do not stop all blood pressure meds without consulting a physician — this may offset Survodutide’s benefits
Stacking Suggestions
Tirzepatide or Semaglutide (alternate between cycles to prevent GLP-1 receptor desensitization)
NAD+ or MOTS-C – enhances cellular energy production and mitochondrial repair alongside fat loss
AOD-9604 – further supports lipolysis during Survodutide’s appetite-suppressing phase
L-Carnitine Injections – promotes fat transport into mitochondria for oxidation
Glutathione – reduces oxidative stress and supports liver function (especially in MASH patients)
CJC-1295/Ipamorelin – enhances lean muscle gain during weight loss phases
For metabolic and liver optimization, Survodutide + Glutathione + NAD+ is a powerful triad. For fat loss, stack with AOD-9604 and CJC-1295/Ipamorelin to preserve lean mass and recover faster.
Please complete your information below to login.
Sign In
Create New Account